Praxis Extends Relutrigine Review to October 2027 for Encephalopathies
0h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
praxis-precision-medicinesfda-extension
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Praxis Precision Medicines announced on June 29, 2026, that the U.S. Food and Drug Administration extended the Prescription Drug User Fee Act action date for its drug candidate relutrigine. The new deadline for a regulatory decision is October 27, 2027, a 15-month extension from the original July 2026 date. The delay was granted to allow more time for the agency to review a recent major amendment to the marketing application.
Regulatory extensions are not uncommon for complex neurological therapies targeting rare diseases with high unmet need. In February 2023, the FDA extended its review of UTI Limited’s vibegron for a similar three-month period to assess additional data. The current macro backdrop for biotech is challenging, with the XBI biotech ETF down 4% year-to-date amidst persistent pressure on speculative, pre-revenue companies.
The extension was triggered by Praxis submitting a substantial amendment to its New Drug Application. This submission typically includes significant new analyses or data sets that were not part of the original filing. For a disorder as complex as SCN8A-developmental and epileptic encephalopathy, the FDA requires extensive time to validate patient data and clinical endpoints. This ensures the safety and efficacy profile is thoroughly vetted for a vulnerable pediatric population.
The new PDUFA date of October 27, 2027, represents a significant 15-month delay from the anticipated mid-2026 decision. Praxis's stock price declined 18% in after-hours trading following the announcement, reflecting immediate investor disappointment. The company's market capitalization fell by approximately $65 million based on its 12.5 million outstanding shares.
This setback contrasts with the performance of broader market indices. The SPDR S&P Biotech ETF (XBI) is down 4% for the year, while the Nasdaq Composite has gained 8% over the same period. The extension also pushes potential drug launch revenues well into 2028, significantly impacting near-term financial projections for the clinical-stage company.
| Metric | Before Announcement | After Announcement | Change |
|---|---|---|---|
| PDUFA Date | July 2026 | October 2027 | +15 months |
| Stock Price | $9.50 | $7.80 | -18% |
The delay is a negative development for Praxis (PRAX) and highlights the regulatory hurdles for neurology-focused biotech firms. Companies with similar rare disease pipelines, such as Marinus Pharmaceuticals (MRNS) and Neurocrine Biosciences (NBIX), may face increased investor scrutiny regarding their regulatory timelines. Conversely, the news may create a short-term advantage for makers of competing anti-seizure medications.
A primary counter-argument is that a more thorough review could ultimately strengthen the drug's label if approved, potentially leading to better commercial uptake. The major risk remains a complete response letter if the new data fails to satisfy the FDA’s requirements. Trading flow immediately shifted toward short-side pressure on PRAX, while some long-term holders may view the dip as a buying opportunity for a de-risked asset.
The next major catalyst for Praxis is the FDA’s feedback on the amended application, expected by the end of the third quarter of 2026. Investors should monitor the company’s cash runway, as a prolonged review process increases burn rates. Key levels to watch for PRAX stock include the 52-week low of $6.50, which could serve as a support level.
Should the FDA request an advisory committee meeting, its date would be a critical volatility event. The outcome of ongoing open-label extension studies for relutrigine will also provide important long-term safety and efficacy data. The Biogen partnership on another asset, PRAX-222, remains a secondary catalyst for the stock in early 2027.
An extension grants the FDA additional time to review submitted data, often because the application was amended with new information. It is a procedural response, not a judgment on the drug's merit. While delays can signal a more complex review, they do not necessarily predict the final outcome, which can still be an approval, a rejection, or a request for more data.
The 15-month extension is longer than the typical three-month delay often seen with major amendments. This length is more comparable to extensions for novel gene therapies, reflecting the complexity of treating rare epileptic encephalopathies. It underscores the regulatory caution applied to neurological drugs for pediatric populations, where risk-benefit assessments are extremely stringent.
SCN8A-DEE is an ultra-rare condition, affecting an estimated 1 in 100,000 births. With approximately 35,000 births per day in the U.S., this implies a very small patient population of a few hundred to a few thousand individuals. This limited market size makes the commercial viability highly dependent on achieving a premium price point for the therapy.
The FDA's extended review intensifies the execution risk for Praxis's lead drug candidate.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.